Comparative efficacy of duo-gargling withsodium bicarbonate solution and Benzydaminehydrochloride (Difflam®) to single gargling withBenzydamine hydrochloride (Difflam®) in headand neck cancer participants who are receivingconcurrent chemoradiotherapy for mucositisprevention and quality of life assessment: apreliminary analysis
Journal of Medical Bioscience · 2026 · 8 · 9-19
DOI: 10.58837/chula.jmbs.8.suppl.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Bioscience, 2026. Verfasst von Siraphob Sriprasert und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Radiation-induced oral mucositis (RIOM) is a common complication of concurrent chemoradiotherapy(CCRT) in head and neck cancer (HNC). Benzydamine HCl is an established anti-inflammatory rinse for preventing RIOM,but it is not known whether adding sodium bicarbonate, which buffers oral pH and reduces microbial load, provides anyadded benefit.
Objective
To compare duo-gargling (Benzydamine HCl followed by sodium bicarbonate) with Benzydamine HCl alone forRIOM prevention in HNC patients receiving cisplatin-based CCRT.
Methods
In this preliminary analysis of a single-center, randomized, single-blinded trial, HNC patients receiving curative-intent CCRT were randomized 1:1 to duo-gargling or single gargling four times daily. The primary endpoint was the blinded-assessed Oral Mucositis Assessment Scale (OMAS) score at week 7. Secondary endpoints included CTCAE v5.0 gradingand supportive-care needs. Mixed-effects models were used for longitudinal analysis.
Results
Twenty-one patients were analyzed (duo-gargling n = 10; single gargling n = 11) with balanced baselinecharacteristics. Mean week-7 OMAS score did not differ between groups (17.20 ± 4.89 vs. 18.55 ± 7.84; mean difference 1.35,95% CI −4.19 to 6.88; P = 0.647), and there was no significant difference at any week. Grade ≥3 mucositis at week 7 waslower with duo-gargling (10.0% vs. 36.4%) but not significant. Opioid prescription at week 3 was significantly lower withduo-gargling (0.0% vs. 45.5%; P = 0.035).
Conclusion
In this preliminary analysis, adding sodium bicarbonate to Benzydamine HCl did not significantly reduceOMAS scores compared with Benzydamine HCl alone. Duo-gargling did show fewer severe mucositis events and lowerearly opioid use, but these findings need to be confirmed in the full study.
Zitieren
APA
Sriprasert, S., Prayongra, A., & Vinayanuwattikun, C. (2026). Comparative efficacy of duo-gargling withsodium bicarbonate solution and Benzydaminehydrochloride (Difflam®) to single gargling withBenzydamine hydrochloride (Difflam®) in headand neck cancer participants who are receivingconcurrent chemoradiotherapy for mucositisprevention and quality of life assessment: apreliminary analysis. Journal of Medical Bioscience, 8, 9-19. https://doi.org/10.58837/chula.jmbs.8.suppl.2
Vancouver
Sriprasert S, Prayongra A, Vinayanuwattikun C. Comparative efficacy of duo-gargling withsodium bicarbonate solution and Benzydaminehydrochloride (Difflam®) to single gargling withBenzydamine hydrochloride (Difflam®) in headand neck cancer participants who are receivingconcurrent chemoradiotherapy for mucositisprevention and quality of life assessment: apreliminary analysis. Journal of Medical Bioscience. 2026;8:9-19. doi:10.58837/chula.jmbs.8.suppl.2
BibTeX
@article{Sriprasert2026,
author = {Sriprasert, Siraphob and Prayongra, Anussara and Vinayanuwattikun, Chanida},
title = {Comparative efficacy of duo-gargling withsodium bicarbonate solution and Benzydaminehydrochloride (Difflam®) to single gargling withBenzydamine hydrochloride (Difflam®) in headand neck cancer participants who are receivingconcurrent chemoradiotherapy for mucositisprevention and quality of life assessment: apreliminary analysis},
journal = {Journal of Medical Bioscience},
year = {2026},
volume = {8},
pages = {9--19},
doi = {10.58837/chula.jmbs.8.suppl.2}
}
EUVIMED